CORRECTED-Novartis lung drug not inferior to GSK's Seretide, study shows

Fri Apr 25, 2014 4:18am EDT

Related Topics

(Removes paragraph on QVA149, which refers to Ultibro Breezhaler not Onbrez Breezhaler)

ZURICH, April 25 (Reuters) - Patients taking Novartis' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline's Seretide, the Swiss drugmaker said on Friday, citing a late stage study.

The Phase IV study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis' once-daily drug showed similar benefits in reducing shortness of breath as GSK's Seretide, which must be taken twice daily.

Around 210 million people worldwide suffer from COPD, a disease that causes breathing trouble and chronic coughing, and is sometimes fatal. (Reporting by Caroline Copley; Editing by Edwina Gibbs and Jane Baird)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.